Table 1. Clinical and laboratory characteristics of study population.
| Code | ST | Source | Colistin MIC | Meropenem MIC | Carbapenemase | Empirical Therapy | Pre-exposure time to colistin | Active Therapy | Duration of Active Colistin Therapy | Survival | 30-day Mortality | Clonal Relatedness |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| K704 | 235 | Catheter | >64 | 16 | OXA-48, NDM-1 | Meropenem Vancomycin | 0 | 0 | 0 | Ex | 1 | |
| K741 | 235 | BAL | 16 | 16 | OXA-48, NDM-1 | Moxifloxacin | 0 | Meropenem Colistin Ertapenem | 1 | Ex | 2 | * |
| K740 | 3078 | BAL | >64 | 8 | OXA-48, NDM-1 | Piperacillin Tazobactam | 0 | Meropenem Colistin Ertapenem | 27 | Ex | 30 | |
| K748 | 235 | DTA | 64 | 16 | OXA-48, NDM-1 | 0 | 0 | 0 | 0 | Discharge | Discharge | * |
| K752 | 3078 | DTA | 4 | 16 | OXA-48, NDM-1 | 0 | 0 | 0 | 0 | Discharge | Discharge | ** |
| K753 | 3078 | BAL | 4 | 8 | OXA-48, NDM-1 | Piperacillin Tazobactam | 0 | Meropenem Colistin | 14 | Discharge | Discharge | ** |
| K783 | 235 | BAL | 16 | 16 | OXA-48, NDM-1 | Meropenem Colistin | 10 | Meropenem Colistin | 10 | Ex | 7 | |
| K970 | 235 | Catheter | 32 | 16 | NDM-1 | Levofloxacin Colistin | 21 days | 0 | 0 | Ex | 10 | |
| K982 | 235 | BAL | 16 | 16 | OXA-48, NDM-1 | Colistin (inhalation) | 25 days | 0 | 0 | Ex | 1 | |
| K989 | 235 | Catheter | >64 | 16 | NDM-1 | Meropenem | 0 | Meropenem Colistin | 38 | Ex | 42 | |
| K1009 | 235 | DTA | 16 | 16 | OXA-48, NDM-1 | Colistin (inhalation) | 8 days | 0 | 0 | Ex | 19 |
Notes: BAL: Bronchoalveolar lavage; DTA: Deep tracheal aspirate.
*clone 1, **clone 2.